This table updates an edition published in April to include new data on prices and discounts offered by several Indian manufacturers of generic antiretrovirals, with the brand names of their products where available, and the terms of the discounted deals for generic drugs.
This table will continue to be updated in line with new developments and offers - please forward any relevant information to the editor Keith Alcorn.
Unicef, UNAIDS, WHO and MSF recently published a price list for drugs and diagnostics for people living with HIV which includes indicative prices for drugs used to treat opportunistic infections and antibody testing kits.
Join an online discussion about making treatments affordable for resource poor countries at www.aidsmap.com.
|
Generic name |
Brand name |
Initials |
Manufacturer |
Discount price |
Special provisions |
Generic alternative (Country/manufacturer name) |
|
Protease inhibitors |
||||||
|
Lopinavir/ritonavir |
Kaletra |
N/a |
Abbott |
c.$1,000 per year |
Africa (available to private sector or company health plans and NGOs, as well as govts) |
None |
|
Ritonavir |
Norvir |
N/a |
Abbott |
c. $1,000 |
Africa (available to private sector or company health plans and NGOs, as well as govts) |
India (Hetero - c. $4300 p.a) |
|
Nelfinavir |
Viracept |
N/a |
Roche |
$1800 p.a |
Sub-Saharan Africa |
India (Hetero - $2248 p.a) |
|
Saquinavir |
Fortovase |
N/a |
Roche |
c. $2400 at 1800mg qd |
15% discount for sub-Saharan Africa |
India (Hetero - $992 p.a.) |
|
Indinavir |
Crixivan |
N/a |
Merck |
$600 per year |
Africa Romania Haiti Brazil Available to NGOs and company health plans, as well as govts |
India: CIPLA - $2300 p.a at 800mg tid) Hetero - $1840 p.a. at 800mg tid) |
|
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) |
||||||
|
Nevirapine |
Viramune |
Boehringer Ingelheim |
Free as two doses for mother and infant treatment $1.22 per day for adult dosing ($445 p.a) |
Maternal/infant treatment free to all non-EU countries (also excludes USA, Canada, NZ, Australia, Japan, Switzerland, Norway, Iceland) |
India: Cipla (Nevimune $197 p.a to non-profits) |
|
|
Efavirenz |
Stocrin |
N/a |
Merck |
$500 per year |
Africa Romania Haiti Brazil ($846 pa) Available to NGOs and company health plans, as well as govts |
India (Aurobindo $485 p.a) |
|
Nucleoside analogues (NRTIs) |
||||||
|
Stavudine |
Zerit |
D4T |
Bristol Myers Squibb |
15 cents a day/$54 per year |
Not available to private sector/company health plans |
India: Cipla (Stavir; $40 p.a to non-profits) Thailand Brazil |
|
Didanosine |
Videx |
ddI |
Bristol Myers Squibb |
80 cents per day/ $310 p.a. |
Not available to private sector/company health plans |
Not patented in Africa Thailand: non-buffered version Brazil India (CIPLA - $584; Aurobindo $190 p.a) |
|
Zidovudine and lamivudine |
Combivir |
AZT and 3TC |
Glaxo Smith Kline |
$2 per day ($730 p.a) |
Developing countries - govts, NGOs and workplace initiatives where suitable medical infrastructure exists, via UNAIDS Accelerating Access Initiative |
India (CIPLA - Duovir $554 pa to non-profits |
|
Zidovudine |
Retrovir |
AZT |
Glaxo Smith Kline |
95% reduction on "average global price" |
As above |
India (CIPLA: Zidovir $306 p.a |
|
Abacavir |
Ziagen |
N/a |
Glaxo Smith Kline |
As above |
||
|
Lamivudine |
Epivir |
3TC |
Glaxo Smith Kline |
58 cents per day |
As above |
CIPLA - India (Lamivir, $109 p.a to non-profits) |
|
Zalcitabine |
Hivid |
ddC |
Roche |
Available at cost |
Brazil |
|
|
Combinations of generics |
||||||
|
Lamivudine, zidovudine and nevirapine |
AZT, 3TC and nevirapine |
CIPLA (India) |
$350 p.a |
Non-profits (Govts $600 p.a) |
||
|
Aurobindo (India) |
$295 p.a |
Offered to govt health progs |
||||
|
Lamivudine, stavudine and nevirapine |
3TC, d4T and nevirapine |
Hetero (India) |
$350 p.a |
Offered to govt health progs |
||